8-K: Longevity Health Holdings Secures $1.96 Million Through ATM Offering, Extends Cash Runway Ahead of 20/20 BioLabs Merger

Longevity Health Holdings, Inc. announced the successful sale of 479,621 shares of common stock through an at-the-market offering, raising approximately $1.96 million and extending its cash runway into Q1 FY26.

Summary

• Longevity Health Holdings, Inc. successfully sold 479,621 shares of its common stock.
• The shares were sold through an at-the-market (ATM) equity offering facility at an average price of $4.08 per share.
• Gross proceeds from the ATM sales totaled approximately $1.96 million, prior to deducting fees and expenses.
• This financing is expected to extend the company's cash runway into Q1 FY26, assuming no growth beyond pro forma consolidated FY24 sales and not factoring in the planned 20/20 merger.
• The company is proceeding with its planned merger with 20/20 BioLabs, Inc.

Sentiment

Score: 8

Explanation: The announcement is largely positive, detailing a successful capital raise that strengthens the company's financial position and extends its cash runway, which are critical for ongoing operations and the planned merger. Management's comments also convey strong confidence.

Positives

• Successfully completed an at-the-market equity offering, demonstrating access to capital markets.
• Raised approximately $1.96 million in gross proceeds, strengthening the company's balance sheet.
• Extended the company's cash runway into Q1 FY26, providing enhanced financial stability.
• Management views the successful ATM offering as a reflection of continued investor confidence in the company's vision and growth strategy.
• The capital raised supports the planned merger with 20/20 BioLabs and the continued delivery of innovative longevity products.

Risks

• The conditions to the closing of the proposed Merger may not be satisfied, including the failure to timely obtain stockholder approval.
• Uncertainties exist regarding the timing of the consummation of the proposed Merger and the ability of each company to complete it.
• Risks related to Longevity Health Holdings' ability to maintain its listing on the Nasdaq Capital Market.
• Challenges in managing operating expenses and expenses associated with the proposed Merger pending its closing.
• Failure or delay in obtaining required approvals from governmental or quasi-governmental entities necessary to consummate the proposed Merger.
• Stockholders of each company could own more or less of the combined company than currently anticipated due to adjustments to the exchange ratio.
• Risks related to the market price of Longevity Health Holdings' common stock relative to the value suggested by the exchange ratio.
• Potential for unexpected costs, charges, or expenses resulting from the transaction.
• Possible adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger.
• The combined company may be unable to obtain sufficient additional capital to continue advancing the commercialization, development, and marketing of its products.
• Risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results.
• The risk that concurrent financing is not consummated prior to the Closing of the Merger.
• Diversion of management's attention from ongoing business operations due to the Merger.
• The possibility of unknown liabilities arising after the Merger.
• Challenges in recognizing anticipated benefits from commercial products, R&D pipeline, distribution agreements, and changes in applicable laws or regulations.
• The company may be adversely affected by other economic, business, and/or competitive factors.
• Other risks and uncertainties detailed in the Annual Report on Form 10-K filed on March 31, 2025, and other SEC reports.

Future Outlook

The company anticipates the launch and commercialization of new products and tests by the combined entity of Longevity Health Holdings and 20/20 BioLabs following the proposed merger. This recent financing is expected to extend the company's cash runway into Q1 FY26, supporting future operations and product development. Additionally, 20/20 BioLabs expects to introduce a new blood test for monitoring chronic inflammation this quarter.

Management Comments

• "We are pleased to strengthen our balance sheet further as we move forward with our planned merger with 20/20 and the continued delivery of innovative longevity products to our customers." Rajiv Shukla, Chairman and Chief Executive Officer of XAGE.
• "This successful ATM offering reflects continued investor confidence in our vision and growth strategy." Rajiv Shukla, Chairman and Chief Executive Officer of XAGE.

Industry Context

Longevity Health Holdings operates within the rapidly evolving longevity and healthy aging sector, focusing on regenerative bio-aesthetics, diagnostics, and nutrition. The strategic merger with 20/20 BioLabs, a company specializing in innovative laboratory tests for early detection and proactive management of chronic diseases, signifies an expansion into broader health diagnostics. This aligns with a growing industry trend towards preventative healthcare, personalized medicine, and integrated wellness solutions, addressing the increasing demand for products and services that promote healthy aging and disease prevention.

Stakeholder Impact

• Shareholders: Experience potential dilution from the ATM offering but benefit from improved financial stability and extended cash runway. Their ownership percentage in the combined company post-merger is subject to exchange ratio adjustments.
• Customers: Can anticipate continued delivery of existing innovative longevity products and the potential introduction of new diagnostic tests from the combined entity.
• Employees: Benefit from increased operational stability and continuity due to the extended cash runway and the strategic plans for the combined company.

Next Steps

• Completion of the proposed merger with 20/20 BioLabs, Inc.
• Launch and commercialization of new products and tests by the combined company (Longevity Health Holdings and 20/20 BioLabs).
• 20/20 BioLabs expects to introduce a new blood test for monitoring chronic inflammation this quarter.
• Filing of relevant materials with the SEC, including Form S-4, Proxy Statement, and prospectus, in connection with the proposed Merger.

Key Dates

Recommendation

Keywords

Longevity Health Holdings, XAGE, ATM offering, equity offering, capital raise, 20/20 BioLabs, merger, regenerative bio-aesthetics, diagnostics, nutrition, Nasdaq, common stock, cash runway, SEC filing, 8-K